Pallas Capital Advisors LLC Fate Therapeutics Inc Transaction History
Pallas Capital Advisors LLC
- $2.43 Billion
- Q2 2025
A detailed history of Pallas Capital Advisors LLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Pallas Capital Advisors LLC holds 15,336 shares of FATE stock, worth $17,483. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,336
Previous 14,232
7.76%
Holding current value
$17,483
Previous $12,000
41.67%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding FATE
# of Institutions
145Shares Held
96.8MCall Options Held
56.7KPut Options Held
5.4K-
Redmile Group, LLC San Francisco, CA12.9MShares$14.7 Million1.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.3MShares$11.8 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$11.5 Million0.0% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY7.79MShares$8.89 Million0.04% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.29MShares$4.89 Million0.0% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $111M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...